Deciphering the role of oncogenic kinase Lemur tyrosine kinase 3 (LMTK3) in breast cancer stem cell mediated multidrug resistance

Breast tumor harbours breast cancer stem cells (bCSCs), responsible for drug resistance or reduced effectiveness of chemotherapy drugs. The bCSCs can escape cell death induced by different treatment modalities, hence can survive and make a replica of the original tumor, contributes to its metastatic spread to distant organs, ultimately causing death. Therefore, targeting the bCSCs is the way forward. LMTK3 protein frequently over-produced in breast cancer cells contributes to drug resistance, and associated with poor survival of BC patients. Anti-LMTK3 peptide, developed by partner, will thus provide novel therapeutic options. The rationale of this study is to define the role of LMTK3 in bCSC-driven cancer progression, and to determine whether shutting down LMTK3 with targeted peptide can overcome drug resistance. Expected benefit to the partner includes: validation of the peptide and innovation in R&D; chances of expanding business networks & collaborations; economic growth; and fetching direct benefit to BC patients.

Taniya Saha
Faculty Supervisor: 
Erique Kiven Lukong
Partner University: